CLINICAL ROLE -
Understand Patient Experiences With Biosimilar Transitions
Study participants’ overall satisfaction with a mandatory nationwide adalimumab transition in New Zealand varied but was generally low.
Read More
To Test or Not to Test—The Million Dollar Question for Patients with C. diff
In the study, a new policy empowered unit-based pharmacists to evaluate the patient’s needs and, when safe, switch from a PPI to an H2 blocker.